Kura Oncology, Inc. (NASDAQ:KURA) Shares Bought by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale lifted its stake in Kura Oncology, Inc. (NASDAQ:KURA) by 216.7% in the fourth quarter, HoldingsChannel reports. The firm owned 95,000 shares of the company’s stock after acquiring an additional 65,000 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Kura Oncology were worth $1,343,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp grew its position in shares of Kura Oncology by 44.1% during the third quarter. State Street Corp now owns 4,368,763 shares of the company’s stock worth $59,677,000 after acquiring an additional 1,337,149 shares during the last quarter. Deerfield Management Company L.P. Series C raised its stake in shares of Kura Oncology by 35.1% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 4,374,044 shares of the company’s stock worth $39,891,000 after buying an additional 1,136,044 shares during the last quarter. BlackRock Inc. grew its position in shares of Kura Oncology by 14.7% in the second quarter. BlackRock Inc. now owns 6,157,402 shares of the company’s stock valued at $65,145,000 after purchasing an additional 788,095 shares during the last quarter. Verition Fund Management LLC acquired a new stake in shares of Kura Oncology during the first quarter valued at $7,930,000. Finally, Goldman Sachs Group Inc. grew its stake in Kura Oncology by 100.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 965,026 shares of the company’s stock worth $17,689,000 after acquiring an additional 483,836 shares during the period.

Kura Oncology Stock Performance

KURA opened at $19.48 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.26 and a current ratio of 12.26. The business’s 50-day simple moving average is $21.01 and its 200 day simple moving average is $14.95. The firm has a market capitalization of $1.48 billion, a PE ratio of -9.37 and a beta of 0.85. Kura Oncology, Inc. has a 52-week low of $7.41 and a 52-week high of $24.17.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. During the same period last year, the company posted ($0.49) EPS. As a group, sell-side analysts expect that Kura Oncology, Inc. will post -2.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on KURA shares. Mizuho began coverage on Kura Oncology in a report on Friday, December 22nd. They issued a “buy” rating and a $26.00 price target for the company. JMP Securities boosted their target price on shares of Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a research note on Wednesday, January 31st. StockNews.com upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, April 3rd. Wedbush reissued an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a report on Wednesday, February 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Wednesday, March 6th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $28.28.

Insider Transactions at Kura Oncology

In other news, CEO Troy Edward Wilson sold 91,052 shares of the company’s stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $20.23, for a total transaction of $1,841,981.96. Following the transaction, the chief executive officer now directly owns 559 shares of the company’s stock, valued at $11,308.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Kura Oncology news, CEO Troy Edward Wilson sold 91,052 shares of the business’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $20.23, for a total value of $1,841,981.96. Following the sale, the chief executive officer now directly owns 559 shares in the company, valued at $11,308.57. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Thomas James Doyle sold 2,318 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $41,260.40. Following the completion of the transaction, the senior vice president now owns 48,093 shares of the company’s stock, valued at approximately $856,055.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 96,919 shares of company stock worth $1,946,415. Company insiders own 5.40% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.